The research team noted that racial subgroups are underrepresented in clinical trials, a factor that should be addressed in ...

It has also instructed clinicians to use the least expensive option among the available treatments for wet AMD, which include Bayer's Eylea (aflibercept) and Novartis' Lucentis (ranibizumab ...

Ranibizumab (Lucentis ... Whatever the case, a doctor will often prescribe antibiotic eye drops to prevent infection.

Novartis and Roche's big-selling eye drug Lucentis has its first biosimilar competitor in Europe, after the European Commission approved Samsung Bioepis' copycat drug Byooviz.

Patients with diabetic macular edema treated with intravitreal aflibercept have a significantly higher risk of adverse renal events compared with those treated with ranibizumab.

The international randomized clinical trial, called RAINBOW, compared ranibizumab to laser therapy for the treatment ... typically takes at least 60 minutes per eye and may require general anesthesia ...

Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting.